Medicure presents Phase 3 MEND-PNPO trial design, baseline data for MC-1 in PNPO deficiency at European Epilepsy Congress

• Medicure presented Phase 3 design, rationale, and baseline data for its MEND-PNPO trial at the 16th European Epilepsy Congress.
• The study is testing MC-1, an oral pharmaceutical-grade vitamin B6 active-form therapy, for an ultra-rare genetic epilepsy disorder.
• Trial progress points to steady enrollment toward a roughly 10-patient target, with some participants already completing one year of treatment.
• Upcoming presentations are scheduled for the Child Neurology Society meeting in October 2026, followed by the American Epilepsy Society meeting in December 2026.
• Program supports a bid to standardize treatment in a niche market with no approved pharmaceutical-grade option, though MC-1 remains unapproved.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicure Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202609081825ACCESSWRNAPR_____1218392) on September 08, 2026, and is solely responsible for the information contained therein.